Roche has received a contract from the Karolinska University Hospital to provide its Human Papillomavirus (HPV) test for primary screening of HPV in Swedish women.
Roche’s cobas HPV Test is a qualitative in-vitro test which detects HPV in patient specimens.
The test utilizes amplification of target DNA by the Polymerase Chain Reaction (PCR) and nucleic acid hybridization for the detection of 14 high-risk (HR) HPV types in a single analysis.
The test identifies types HPV 16 and HPV 18, while concurrently detects the other high risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68).
Roche Diagnostics COO Daniel Day said with the introduction of their new HPV test as the primary screening test, they hope to reduce the number of women who are missed in the early stages and thereby enable earlier intervention before they develop cervical cancer.